Antiviral Effect of Candies Containing Persimmon-Derived Tannin against SARS-CoV-2 Delta Strain.

COVID-19 Delta variant SARS-CoV-2 aerosol infection persimmon-derived tannin saliva

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
27 07 2023
Historique:
received: 23 06 2023
revised: 25 07 2023
accepted: 26 07 2023
medline: 28 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

Inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the mouth has the potential to reduce the spread of coronavirus disease 2019 (COVID-19), due to the virus being readily transmitted by dispersed saliva. Persimmon-derived tannin has strong antioxidant and antimicrobial activity owing to its strong adhesion to proteins, and it also exhibited antiviral effects against non-variant and Alpha-variant SARS-CoV-2 in our previous study. In this study, we first demonstrated the antiviral effects of persimmon-derived tannin against the Delta variant of SARS-CoV-2 in vitro via the plaque assay method. We then examined the effects of candy containing persimmon-derived tannin. Remarkably, the saliva samples provided by healthy volunteers while they were eating tannin-containing candy showed that the virus titers of the SARS-CoV-2 Delta variant were suppressed. In addition, we found that the SARS-CoV-2 viral load in saliva from patients with COVID-19 collected immediately after they had eaten the tannin-containing candy was below the level of detection via PCR for SARS-CoV-2. These data suggest that adding persimmon-derived tannin to candy and holding such candy in the mouth is an effective method for inactivating SARS-CoV-2 in saliva, and the application of this approach shows potential for inhibiting the transmission of COVID-19.

Identifiants

pubmed: 37631980
pii: v15081636
doi: 10.3390/v15081636
pmc: PMC10459621
pii:
doi:

Substances chimiques

Antiviral Agents 0
Tannins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Front Microbiol. 2022 Jan 03;12:786042
pubmed: 35046915
Eur J Med Chem. 2023 Sep 5;257:115503
pubmed: 37229831
Emerg Infect Dis. 2021 Apr;27(4):1146-1150
pubmed: 33754989
Int J Oral Sci. 2020 Apr 17;12(1):11
pubmed: 32300101
J Hosp Infect. 2021 Jul;113:30-43
pubmed: 33865974
Biomedicines. 2021 Jun 18;9(6):
pubmed: 34207313
BMJ. 2022 Mar 9;376:e069761
pubmed: 35264324
Sci Rep. 2021 Mar 31;11(1):7286
pubmed: 33790314
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
Mol Nutr Food Res. 2009 Sep;53 Suppl 2:S310-29
pubmed: 19437486
CMAJ. 2021 Oct 25;193(42):E1619-E1625
pubmed: 34610919
Western Pac Surveill Response J. 2022 Sep 16;13(3):1-10
pubmed: 36688179
MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):350-354
pubmed: 33705364
PLoS One. 2017 Aug 21;12(8):e0183489
pubmed: 28827842
J Funct Foods. 2022 Dec;99:105356
pubmed: 36467850
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Nat Rev Microbiol. 2023 Mar;21(3):178-194
pubmed: 36631691
Sci Rep. 2021 Dec 8;11(1):23695
pubmed: 34880383
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Nat Rev Microbiol. 2023 Jun;21(6):361-379
pubmed: 37020110
PLoS One. 2013;8(1):e55343
pubmed: 23372851
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
Nat Med. 2021 May;27(5):892-903
pubmed: 33767405

Auteurs

Ryutaro Furukawa (R)

Department of Immunology, Nara Medical University, Kashihara 6348521, Japan.

Masahiro Kitabatake (M)

Department of Immunology, Nara Medical University, Kashihara 6348521, Japan.

Noriko Ouji-Sageshima (N)

Department of Immunology, Nara Medical University, Kashihara 6348521, Japan.

Dai Tomita (D)

Department of Respiratory & Internal Medicine, National Hospital Organization Nara Medical Center, Nara 6308053, Japan.

Makiko Kumamoto (M)

Department of Respiratory & Internal Medicine, National Hospital Organization Nara Medical Center, Nara 6308053, Japan.

Yuki Suzuki (Y)

Department of Microbiology and Infectious Diseases, Nara Medical University, Kashihara 6348521, Japan.

Akiyo Nakano (A)

Department of Microbiology and Infectious Diseases, Nara Medical University, Kashihara 6348521, Japan.

Ryuichi Nakano (R)

Department of Microbiology and Infectious Diseases, Nara Medical University, Kashihara 6348521, Japan.

Yoko Matsumura (Y)

Department of Immunology, Nara Medical University, Kashihara 6348521, Japan.
Department of Health and Nutrition, Faculty of Health Science, Kio University, Koryo 6350832, Japan.

Shin-Ichi Kayano (SI)

Department of Health and Nutrition, Faculty of Health Science, Kio University, Koryo 6350832, Japan.

Hisakazu Yano (H)

Department of Microbiology and Infectious Diseases, Nara Medical University, Kashihara 6348521, Japan.
MBT (Medicine-Based Town) Institute, Nara Medical University, Kashihara 6348521, Japan.

Shinji Tamaki (S)

Department of Respiratory & Internal Medicine, National Hospital Organization Nara Medical Center, Nara 6308053, Japan.

Toshihiro Ito (T)

Department of Immunology, Nara Medical University, Kashihara 6348521, Japan.
MBT (Medicine-Based Town) Institute, Nara Medical University, Kashihara 6348521, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH